{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:12:50Z","timestamp":1785255170308,"version":"3.55.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cangzhou science and technology project","award":["No. 162302016"],"award-info":[{"award-number":["No. 162302016"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Congenital heart disease in children with pulmonary hypertension is a common and serious complication, which has a direct impact on the surgical effect and prognosis of children. Bosentan and vardenafil are commonly used drugs for the treatment of postoperative pulmonary hypertension in children with congenital heart disease, and there are few clinical studies on their combined use. Therefore, the purpose of this randomized controlled trial is to evaluate the effectiveness and safety of the combined use of 2 drugs in the treatment of postoperative pulmonary hypertension in children with congenital heart disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This is a prospective randomized controlled trial to study the effectiveness and safety of bosentan combined with vardenafil in the treatment of postoperative pulmonary hypertension in children with congenital heart disease. Approved by the clinical research ethics committee of our hospital. The patients were randomly divided into 1 of 2 treatment regimens:<\/jats:p>\n            <jats:p>Patients, doctors, nurses, and data collection assistants were blinded to group allocation. Observation indicators include: oxyhemoglobin saturation (SpO2), 6-min Walking Test Distance (6 MWTD), systolic pulmonary artery pressure, mean pulmonary artery pressure, Borg score, NYHAFC score, etc. Data were analyzed using the statistical software package SPSS version 25.0 (Chicago, IL).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>This study will evaluate the effectiveness and safety of bosentan combined with vardenafil in the treatment of pulmonary hypertension after congenital heart disease in children. The results of this experiment will provide a clinical basis for the use of bosentan combined with vardenafil to treat pulmonary hypertension after congenital heart disease in children.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Ethics and dissemination:<\/jats:title>\n            <jats:p>Private information from individuals will not be published. This systematic review also does not involve endangering participant rights. Ethical approval was not required. The results may be published in a peer-reviewed journal or disseminated at relevant conferences.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OSF Registration number:<\/jats:title>\n            <jats:p>DOI 10.17605\/OSF.IO\/962BT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000023896","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:39:19Z","timestamp":1610584759000},"page":"e23896","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["The efficacy of bosentan combined with vardenafil in the treatment of postoperative pulmonary hypertension in children with congenital heart disease"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2068-6586","authenticated-orcid":false,"given":"Chao","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runhan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manting","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/HCO.0000000000000251","article-title":"Recognition and management of arrhythmias in adult congenital heart disease","volume":"31","author":"McLeod","year":"2016","journal-title":"Curr Opin Cardiol"},{"key":"R2-20250504","first-page":"355","article-title":"Pulmonary arterial hypertension: modern diagnostics and therapy--Part 1","volume":"34","author":"Betkier-Lipi\u0144ska","year":"2013","journal-title":"Polski Merkuriusz ekarski"},{"issue":"(6 Suppl)","key":"R3-20250504","doi-asserted-by":"crossref","first-page":"52s","DOI":"10.1378\/chest.09-2861","article-title":"Pulmonary hypertension associated with congenital heart disease: pulmonary vascular disease: the global perspective","volume":"137","author":"Adatia","year":"2010","journal-title":"Chest"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1378\/chest.06-2674","article-title":"Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines","volume":"131","author":"Badesch","year":"2007","journal-title":"Chest"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/1755-5922.12111","article-title":"Treatment of secondary pulmonary hypertension with bosentan after left ventricular assist device implantation","volume":"33","author":"LaRue","year":"2015","journal-title":"Cardiovasc Therapeut"},{"key":"R6-20250504","first-page":"1846","article-title":"Efficacy of oral bosentan for treatment of congenital heart disease-associated pulmonary arterial hypertension","volume":"34","author":"Weihua","year":"2014","journal-title":"J South Med Univ"},{"key":"R7-20250504","first-page":"762","article-title":"Clinical observation of bosentan combined with vardenafil in treatment of pulmonary arterial hypertension after congenital heart disease operation","volume":"31","author":"Kun","year":"2016","journal-title":"Drugs Clinic"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1249\/00005768-198205000-00012","article-title":"Psychophysical bases of perceived exertion","volume":"14","author":"Borg","year":"1982","journal-title":"Med Sci Sports Exercise"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12471-016-0823-9","article-title":"Erratum to: Tachyarrhythmia in patients with congenital heart disease: inevitable destiny","volume":"24","author":"Teuwen","year":"2016","journal-title":"Netherlands Heart J"},{"key":"R11-20250504","first-page":"315","article-title":"The risk factors of death in patients with congenital heart disease-related pulmonary hypertension and the clinical characteristics of different subtypes","author":"Zhuoyuan","year":"2020","journal-title":"Chin J Cardiol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11906-016-0657-2","article-title":"Anticoagulation in pulmonary arterial hypertension","volume":"18","author":"Robinson","year":"2016","journal-title":"Curr Hypertens Rep"},{"key":"R13-20250504","first-page":"109","article-title":"Pulmonary arterial hypertension: pathophysiology and advances in medication","volume":"35","author":"Lu","year":"2019","journal-title":"J Clin Cardiol"},{"key":"R14-20250504","first-page":"334","article-title":"Pharmacological mechanism and evaluation of clinical application of Bosentan for treatment of pulmonary artery hypertension","author":"Jin","year":"2005","journal-title":"Eval Anal Drug-Use Hosp China"},{"key":"R15-20250504","first-page":"206","article-title":"Application progress of bosentan in patients with congenital heart disease and pulmonary hypertension","volume":"31","author":"Hailong","year":"2016","journal-title":"Chin Circ J"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/icvts\/ivx108","article-title":"Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan","volume":"25","author":"Ried","year":"2017","journal-title":"Interact Cardiovasc Thor Surg"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11886-017-0889-z","article-title":"Evaluation and management of erectile dysfunction in the hypertensive patient","volume":"19","author":"Patel","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00424-017-1937-7","article-title":"The regulation of transient receptor potential canonical 4 (TRPC4) channel by phosphodiesterase 5 inhibitor via the cyclic guanosine 3\u20195\u2019-monophosphate","volume":"469","author":"Wie","year":"2017","journal-title":"Pflugers Archiv"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijcard.2010.10.051","article-title":"Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology","volume":"155","author":"D\u2019Alto","year":"2012","journal-title":"Int J Cardiol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur Resp J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:25:40Z","timestamp":1746339940000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023896"}},"subtitle":["A protocol of randomized controlled trial"],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000023896","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"2020-11-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}